Chembio Diagnostics Inc. (CEMI: Quote) announced Friday morning that it received FDA approval for its Dual Path Platform HIV 1/2 assay for the rapid, point-of-care detection of HIV-1/2 antibodies in either oral fluid or blood samples.
Chembio Diagnostics gapped up sharply Friday and has spiked higher in early trade on above average volume. The stock is now up 1.15 at $5.75 and has surged to a new high for the year.
by RTT Staff Writer
For comments and feedback: email@example.com